We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Molecular Pathway That Enables Movement of Metastatic Cancer Cells Identified

By LabMedica International staff writers
Posted on 16 Oct 2011
Cancer researchers have identified a molecular pathway that seems to be responsible for the ability of metastatic tumor cells to change shape and travel.

Investigators at the University of Michigan (Ann Arbor, USA) worked with breast cancer cells growing in culture. More...
Previous studies had shown that aggressively metastatic breast cancer cells usually overexpressed the RhoC (aplysia ras-related homolog 9) gene. In this study, they searched for the molecular trigger for RhoC expression.

They reported in the August 23, 2011, online edition of the journal Cancer Research that the protein p38gamma was directly linked to RhoC activation. P38gamma is one member of the p38 MAPK (p38 mitogen-activated protein kinase) class of mitogen-activated protein kinases. These enzymes are responsive to stress stimuli, such as cytokines, ultraviolet irradiation, heat shock, and osmotic shock, and are involved in cell differentiation and apoptosis.

Results from experiments with breast cancer cell cultures revealed that inactivation of p38gamma caused cells to flatten out and shift from fast motion to ineffective movement. Clinical relevance indicated that elevated expression of p38gamma was associated with lower overall survival of breast cancer patients. The critical role of p38gamma was further emphasized by data generated from a mathematical model that described how various molecules contributed to cell movement.

“Normal motion is commonly seen in aggressive cancers, which is why it is very important to understand what the key switches are for this motion,” said senior author Dr. Sofia Merajver, professor of internal medicine at the University of Michigan. “Cell movement is very difficult to observe, which is why mathematical modeling in oncology is valuable. This gives us a more complete understanding of how aggressive breast cancer cells move and the influence of p38gamma in particular on modifying this motion.”

“We do have targeted therapies in the clinic, but the total burden of disease that they ameliorate is still relatively minimal. The reasons may not necessarily be that they are not good drugs, but simply that we do not understand how they work, because we do not understand the biology in sufficient detail. That’s why studies like this are so important in advancing drug development,” said Dr. Merajver.

Related Links:
University of Michigan



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Chromogenic Culture System
InTray™ COLOREX™ ECC
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers identified 157 metabolites linked to BBB damage, including 25 that appeared in at least two independent studies (Image Credit: Adobe Stock)

Blood Metabolite Patterns May Enable Early Detection of Blood-Brain Barrier Injury

Early injury to the blood-brain barrier (BBB) can precede many neurological disorders but remains difficult to detect noninvasively. Laboratory markers that identify barrier dysfunction before symptoms... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.